Role of Blood Transfusion in Transplantation: A Review

ABSTRACT

The ultimate goal of transplantation immunology is induction of donor-specific tolerance without the need for chronic immunosuppression. A number of strategies have been used to induce tolerance, including donor-specific blood transfusion (DST). A large number of experimental and clinical studies have evaluated the ability of DST to induce tolerance in solid organ transplantation. In contrast, a limited number of experimental studies have been reported evaluating the effect of DST in induction of tolerance in composite tissue allograft transplants.

DST applications include cadaveric and living-related graft recipients in humans, leading to achievement of microchimerism. Although the mechanism of action is still uncertain, microchimerism with the concomitant persistence of soluble donor HLA antigen is considered to be the most significant contributing factor.

In this article, the experimental and clinical applications, as well as the immunomodulatory mechanism of DST, are reviewed.

Donor-specific blood transfusion - composite tissue allograft - tolerance strategies

REFERENCES

• 1 Opelz G, Sengar D P, Mickey M R, Terasaki P I. Effect of blood transfusions on subsequent kidney transplants.  Transplant Proc. 1973;  5 253-259
• 2 Brynger H, Frisk B, Ahlmen J. Graft survival and blood transfusion. In: Robinson BH Proceedings of the XIV Congress of the European Dialysis and Transplant Association. Kent, England; Pitman Medical Publishing Co 1997: 290-295
• 3 Pfaff W W, Fennell R S, Howard R J. Planned random donor blood transfusion in preparation for transplantation.  Transplantation. 1984;  38 701-703
• 4 Okazaki H, Maki T, Wood M L. Effect of blood transfusions on skin allograft survival in immunosuppressed mice.  Transplant Proc. 1981;  13 515-517
• 5 Frisk B, Brynger H, Sandberg L. Two random transfusions before primary renal transplantation-four years experience from a single center.  Transplant Proc. 1982;  14 386-388
• 6 Faver C, Jeannet M, Harder F. Blood transfusions, cytotoxic antibodies, and kidney graft survival.  Transplantation. 1979;  28 343-346
• 7 Salvatierra O, Vincenti F, Ahmend W J. What about blood transfusions in living related transplantation? Abstracts of the American Society of Nephrology, Twelfth Annual Meeting. Boston, Massachusetts; 1979: 178A
• 8 Kerman R H, Susskind B, Katz S M, Van Buren C T, Kahan B D. Post renal transplant MLR hypo-responders have fewer rejections and better graft survival than MLR hyper-responders.  Transplant Proc. 1997;  29 1410-1411
• 9 Kerman R H, Katz S M, Schoenberg L, Baraket O, Van Buren C T, Kahan B D. 10-year follow up of MLR-hyporesponsive living related cyclosporine monotherapy treated renal allograft recipients.  Transplant Proc. 1997;  29 198-199
• 10 Jackson A, McSherry C, Butters K et al.. Pretransplant exposure to donor HLA-DR antigen in random transfusion units and the development of donor antigen-specific hyporeactivity.  Human Immunology. 1997;  55 148-153
• 11 Salvatierra O, Vincenti F, Amend W et al.. Deliberate donor-specific blood transfusions prior to living related renal transplantation: a new approach.  Ann Surg. 1980;  192 544
• 12 Opelz G, Terasaki P I. Dominant effect of transfusions on kidney graft survival.  Transplantation. 1980;  29 153-158
• 13 Salvatierra O, Vincenti F, Ahmend W JC. Four year experience with donor-specific blood transfusions.  Transplant Proc. 1983;  15 924
• 14 Potter D, Garovoy M, Hopper S et al.. Effect of donor specific transfusion on renal transplantation.  Pediatrics. 1985;  76 402-405
• 15 Broyer M, Gagnadoux M, Guest G et al.. Kidney transplantation in children: results of 383 grafts performed at Enfants Malades Hospital from 1973-1984. In: Hamgurger J, Grosnier J, Grunfeld P, Maxwell MD Advances in Nephrology. Chicago, IL; Year Book Medical Publishers 1987 307
• 16 Chavers B M, Nevins T E, Knaack M et al.. Early acute tubular necrosis, late rejection in pediatric renal transplantation with donor specific transfusion.  Transplant Proc. 1987;  19 1526-1527
• 17 Kahan B D, Van Buren C T, Flechner S M, Payne W D, Boileau M, Kerman R H. Cyclosporine immunosuppression mitigates immunologic risk factors in renal allotransplantation.  Transplant Proc. 1983;  15 2469-2478
• 18 Lundgren G, Albrechtsen D, Flatmark A et al.. HLA-matching and pretransplant blood transfusions in cadaveric renal transplantation-a changing picture with cyclosporin.  Lancet. 1986;  2 66-69
• 19 Opelz G. Improved kidney graft survival in nontransfused recipients.  Transplant Proc. 1987;  19 149-152
• 20 Cecka J M, Cicciarelli J, Mickey M R, Terasaki P I. Blood transfusions and HLA matching-an either/or situation in cadaveric renal transplantation.  Transplantation. 1988;  45 81-86
• 21 Dubernard J M, Owen E, Herzberg G et al.. Human hand allograft: report on first 6 months.  Lancet.. 1999;  353 1315-1320
• 22 Siemionow M, Gozel-Ulusal B, Engin Ulusal A et al.. Functional tolerance following face transplantation in the rat.  Transplantation.. 2003;  75 1607-1609
• 23 Siemionow M, Oke R, Ozer K et al.. Induction of donor-specific tolerance in rat hind-limb allografts under antilymphocyte serum and cyclosporine A protocol.  J Hand Surg. 2002;  27A 1095-1103
• 24 Buttemeyer R, Jones N F, Min Z et al.. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine.  Plast Reconstr Surg. 1996;  97 139-148
• 25 Kamel G, Stephan A, Masri M A et al.. Donor-specific transfusion under the new cyclosporine A formulation Consupren versus azathioprine, Imuran.  Transplant Proc. 1997;  29 2960-2961
• 26 Whelchel J D, Shaw J F, Curtis J J, Luke R G, Diethelm A G. Effect of pretransplant stored donor-specific blood transfusions on early renal allograft survival in one-haplotype living related transplants.  Transplantation. 1982;  34 326-329
• 27 Cheigh J S, Suthanthiran M, Fotino M et al.. Minimal sensitization and excellent renal allograft outcome following donor-specific blood transfusion with a short course of cyclosporine.  Transplant Proc. 1991;  23 1023
• 28 Otsuka M, Yuzawa K, Takada Y et al.. Long-term graft survival of living-related kidneys after donor-specific transfusion.  Transplant Proc. 2000;  32 1741-1742
• 29 Black K S, Hewitt C W, Woodard T L et al.. Efforts to enhance survival of limb allografts by prior administration of whole blood in rats using a new survival end-point.  J Microsurg. 1982;  3 162-167
• 30 Balshi J D, Francfort J W, Perloff L J. The influence of ultraviolet irradiation on the blood transfusion effect.  Surgery. 1985;  98 243-250
• 31 Lasek W, Jakóbisiak M, Plodzisewska M, Szczytnicki W, Górecki D. The role of drug timing and histoincompatibility barrier in prolongation of cardiac graft survival in mice treated with donor-specific blood and cyclophosphamide.  Immunology Letters. 1988;  17 357-360
• 32 Bradley J A. The blood transfusion effect: experimental aspects.  Immunology Letters. 1991;  29 127-132
• 33 Sato K, Yabuki K, Haba T, Maekawa T. Role of Kupffer Cells in the induction of tolerance after liver transplantation.  J Surg Res. 1996;  63 433-438
• 34 Sato Y, Farges O, Buffello D, Hatakeyama K, Bismuth H. Cytokine mRNA expression in the liver after administration of donor leukocytes.  Transplant Proc. 1998;  30 3855-3857
• 35 Antoniou E A, Drayson M, Howie A J, McMaster P, D'Silva M. Effect of donor-specific transfusion in combination with FK506 in rat cardiac allotransplantation.  Transplant Proc. 1999;  31 2796-2798
• 36 Morin N, Lamoureux E, Lipman M, Tector J, Tchervenkov J I, Metrakos P. Donor-specific portal transfusion augments microchimerism in a porcine model of small bowel transplantation.  Transplant Proc. 2000;  32 1290-1291
• 37 Fecteau A H, Tchervenkov J I, Guttman F M, Takara T, Rosenmann E. Small bowel transplantation: the effect of intraportal donor-specific transfusion 24 hours pretransplant and low-dose cyclosporine Transplantation.  1994;  58 399-402
• 38 Martinelli G P, Chung-Loy R, Sher L. Long-term prolongation of cardiac allografts by subtherapeutic levels of cyclosporine in rats conditioned with pretransplant blood transfusions and cyclosporine.  Transplantation. 1985;  39 1-5
• 39 Yasumura T, Kahan B D. Prolongation of rat kidney allografts by pretransplant administration of donor antigen extract or whole blood transfusion combined with a short course of cyclosporine.  Transplantation. 1983;  36 603-609
• 40 Ahmed S M, Baslaim G, Eshelby D, Guttmann R D, Tchervenkov J I. The effect of transfusion with donor-specific peripheral lymphocytes, whole blood or erythrocytes on cardiac allograft survival in cyclosporine-treated rats.  Transplantation. 1994;  57 634-637
• 41 Ringers J, Ossevoort M, Haanstra K, Kroczek R, Volk D, Jonker M. Blockade of CD154 at the time of donor-specific blood transfusion does not improve kidney graft survival in rhesus monkeys.  Transplant Proc. 2001;  33 524
• 42 Antoniou E A, Drayson M, Howie A J, McMaster P, D'Silva M. Donor-specific blood transfusion does not enhance the effect of FTY720 in rat cardiac allotransplantation.  Transplant Proc. 1998;  30 1042-1043
• 43 Oluwole S F, Fawwaz R A, Reemtsma K, Hardy M A. Induction of donor-specific unresponsiveness to rat cardiac allograft by donor leukocytes and cyclosporine.  Transplantation. 1988;  45 1131-1135
• 44 Kahan B D. Cosmas and Damian revisited.  Transplant Proc. 1983;  15 2211-2216
• 45 Lapchinsky A G, Eingorn A G, Uratkov E F. Homotransplantation of extremities in tolerant dogs observed up to seven years.  Transplant Proc. 1973;  5 773-779
• 46 Kim S K, Aziz S, Oyer P, Hentz V R. Use of cyclosporin A in allotransplantation of rat limbs.  Ann Plast Surg. 1984;  12 249-255
• 47 Stark G B, Swartz W M, Narayanan K, Moller A R. Hand transplantation in baboons.  Transplant Proc. 1987;  19 3968-3971
• 48 Daniel R K, Egerszegi E P, Samulack D D, Skanes S E, Dykes R W, Rennie W R. Tissue transplants in primates for upper extremity reconstruction: a preliminary report.  J Hand Surg. 1986;  11 1-8
• 49 Hotokebuchi T, Arai K, Takagishi K, Arita C, Sugioka Y, Kaibara N. Limb allografts in rats immunosuppressed with cyclosporine: as a whole-joint allograft.  Plast Reconstr Surg. 1989;  83 1027-1038
• 50 Kniha H, Randzio J, Gold M E et al.. Growth of forelimb allografts in young rabbits immunosuppressed with cyclosporine.  Ann Plast Surg. 1989;  22 135-141
• 51 Xu H, Montgomery S P, Preston E H et al.. Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation.  J Immunol.. 2003;  170 2776-2782
• 52 Nomoto K, Kanoh K, Suzuki H, Shimura T, Kuwano H. Mechanism of hyporesponsiveness caused by donor-specific transfusion to allogeneic minor antigens.  Eur Surg Res.. 2001;  33 217-224
• 53 Barbari A, Stephan A, Masri M A, Joubran N, Dagher O, Kamel G. Donor specific transfusion in kidney transplantation: effect of different immunosuppressive protocols on graft outcome.  Transplant Proc. 2001;  33 2787-2788
• 54 Kong J M, Jeong J H, Kang J K, Seong I G, Kim B C. Donor-specific transfusion in living related and unrelated donor kidney transplantation: minimal sensitization and excellent graft outcome.  Transplant Proc. 1995;  27 1036-1037
• 55 Sharma R K, Pai P K, Kumar A et al.. Morphological and morphometric studies on liver in rats subjected to repetitive heat stress.  Nephron. 1997;  75 20-26
• 56 Woodle E S, Newell K A, Haas M et al.. Reversal of accelerated renal allograft rejection with FK506.  Clin Transplant. 1997;  11 251-254
• 57 Lyne J C, Vivas C A, Shapiro R et al.. Cadaveric renal transplantation against a positive crossmatch under tacrolimus immunosuppression: long-term follow-up.  Transplant Proc. 1997;  29 312
• 58 Sato Y, Watanabe H, Yamamoto S et al.. Role of recipient CD56⁺ CD3⁺ cells in the graft in living-related partial liver transplantation.  Transplant Proc. 2000;  32 2131-2132
• 59 Terasaki P I, Cecka J M, Gjertson D W, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors.  N Engl J Med. 1995;  333 333-336
• 60 Okazaki H, Sato T, Miura S, Amada N. Donor-specific blood transfusion in living-related renal transplantation: fourteen-year experience.  Transplant Proc. 1997;  29 200-202
• 61 Miura S, Okazaki H, Satoh T, Amada N, Ohashi Y. Long-term follow-up of living donor renal transplant recipients sensitized after donor specific blood transfusion.  Transplant Proc. 2001;  33 1221-1223
• 62 Chen D, Sung R, Bromberg J S. Gene therapy in transplantation.  Transplant Immunology. 2000;  9 301-314
• 63 Liang J, Yamaguchi Y, Matsuda T et al.. Posttransplant infusion of donor-specific blood induces immunological unresponsiveness in rat hepatic allografts.  Transplantation. 2000;  70 1363-1371
• 64 Marquet R L, Heystek G A. Induction of suppressor cells by donor-specific blood transfusions and heart transplantation in rats.  Transplantation. 1981;  31 272-274
• 65 Terasaki P I. The beneficial transfusion effect on kidney graft survival attributed to clonal deletion.  Transplantation. 1984;  37 119-125
• 66 Wendel T D. The beneficial effect of donor-specific transfusions: a review of existing explanations and a new hypothesis based on a relatively unapplied theory of T cell immunoregulation. A regulatory hypothesis in progress.  Med Hypotheses.. 2000;  54 922-943
• 67 Leivestad T, Thorsby E. Effects of HLA-haploidentical blood transfusions on donor-specific immune responsiveness.  Transplantation. 1984;  37 175-181
• 68 Suciu-Foca N, Reed E, Rohowsky C, Kung P, King D W. Anti-idiotypic antibodies to anti-HLA receptors induced by pregnancy.  Proc Natl Acad Sci USA. 1983;  80 830-834
• 69 Kishimoto K, Yuan X, Auchincloss Jr H, Sharpe A H, Mandelbrot D A, Sayegh M H. Mechanism of action of donor-specific transfusion in inducing tolerance: role of donor MHC molecules, donor co-stimulatory molecules, and indirect antigen presentation.  J Am Soc Nephrol. 2004;  15 2423-2428
• 70 Roelen D L, van Rood J J, Brand A, Claas F H. Immunomodulation by blood transfusions.  Vox Sang. 2000;  78 Suppl 2 273-275
• 71 Roelen D, Brand A, Claas F H. Pretransplant blood transfusions revisited: a role for CD(4+) regulatory T cells?.  Transplantation. 2004;  77(1 Suppl) S26-S28
• 72 Burlingham W J, Grailer A P, Fechner J H et al.. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient.  Transplantation. 1995;  59 1147-1155
• 73 Mincheff M S, Meryman H T, Kapoor V et al.. Blood transfusion and immunomodulation: A possible mechanism.  Vox Sang. 1993;  65 18-24
• 74 Macleod A M, Hillis A N, Mather A, Bone J M, Catto G R. Effect of cyclosporin, previous third-party transfusion, and pregnancy on antibody development after donor-specific transfusion before renal transplantation.  Lancet. 1987;  329 416-418
• 75 Horuzsko A, Gyó E, Réti M et al.. Non-cytotoxic blocking antibodies and suppressor cells induced by donor-specific transfusions in healthy volunteers and potential kidney transplant recipients.  Immunology Letters. 1990;  26 127-130
• 76 Josien R, Douillard P, Guillot C et al.. A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance.  J Clin Invest. 1998;  102 1920-1926
• 77 Lagaaij E L, Hennemann I P, Ruigrok M et al.. Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts.  N Engl J Med. 1989;  321 701-705
• 78 Mast B J, Balk A H. Effect of HLA-DR-shared blood transfusion on the clinical outcome of heart transplantation.  Transplantation.. 1997;  63 1514-1519
• 79 Starzl T E, Demetris A J, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance.  Lancet. 1992;  339 1579-1582
• 80 Starzl T E, Demetris A J, Trucco M et al.. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance.  Hepatology. 1993;  17 1127-1152
• 81 Murase N, Starzl T E, Ye Q et al.. Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation: with particular reference to the liver.  Transplantation. 1996;  61 1-4
• 82 Taniguchi H, Toyoshima T, Fukao K, Nakauchi H. Presence of hematopoietic stem cells in the adult liver.  Nat Med. 1996;  2 198-203
• 83 Schlitt H J, Kanehiro H, Raddatz G et al.. Persistence of donor lymphocytes in liver allograft recipients.  Transplantation. 1993;  56 1001-1007
• 84 Demetris A J, Murase N, Starzl T E. Donor dendritic cells after liver and heart allotransplantation under short term immunosuppression.  Lancet. 1992;  339 1610-1611
• 85 Claas F. Towards clinical transplantation tolerance.  Lancet. 2003;  361 1489-1490
• 86 Fandrich F, Lin X, Zhu X, Kloppel G, Parwaresch R, Kremer B. CD95L confers immune privilege to liver grafts which are spontaneously accepted.  Transplant Proc. 1998;  30 1057-1058
• 87 Sharland A, Shastry S, Wang C et al.. Kinetics of intragraft cytokine expression, cellular infiltration, and cell death in rejection of renal allografts compared with acceptance of liver allografts in a rat model.  Transplantation. 1998;  65 1370-1377
• 88 Shirwan H, Wang C, Barwari L, Cramer D V. Recipient-donor microchimerism is not a prerequisite for the maintenance of allograft tolerance.  Transplant Proc. 1997;  61 1182-1183
• 89 Sivasai K SR, Alevy Y G, Duffy B F et al.. Peripheral blood microchimerism in human liver and renal transplant recipients.  Transplantation. 1997;  64 427-432
• 90 Ito H, Hamano K, Gohra H et al.. Role of microchimerism on long-term graft survival after donor-specific transfusion in a rat heart transplantation model.  Transplant Proc. 1998;  30 3862-3864
• 91 Huang Y, Xia J, Yang C, Ye S, Ye Y. IL-10 gene expression and cardiac allograft survival with or without treatment of monoclonal antibodies, CsA, donor-specific transfusion after rat heart transplantation.  J Heart Lung Transplant. 2002;  21 129
• 92 Kataoka M, Margenthaler J A, Ku G, Flye M W. Development of infectious tolerance after donor-specific transfusion and rat heart transplantation.  J Immunol.. 2003;  171 204-211
• 93 Ichiguchi O, Yamaguchi Y, Akizuki E et al.. Prolonged survival of rat hepatic allografts treated with a pretransplant donor-specific blood transfusion is associated with reduced cytokine-induced neutrophil chemoattractant expression.  Transplantation. 1998;  65 465-472
• 94 Oya H, Sato Y, Ichida T et al.. Changes in serum cytokine levels and donor-specific transfusion via portal vein during the early period following living related donor liver transplantation.  Transplant Proc. 2003;  35 409
• 95 Takeuchi T, Lowry R P, Konieczny B. Heart allografts in murine systems. The differential activation of Th2-like effector cells in peripheral tolerance Transplantation.  1992;  53 1281-1294
• 96 Bugeon L, Cuturi M C, Hallet M M, Paineau J, Chabannes D, Soulillou J P. Peripheral tolerance of an allograft in adult rats-characterization by low interleukin-2 and interferon-gamma mRNA levels and by strong accumulation of major histocompatibility complex transcripts in the graft.  Transplantation. 1992;  54 219-225
• 97 Josien R, Doullard P, Guillot C et al.. A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance.  J Clin Invest.. 1998;  102 1920-1926
• 98 Inuzuka S, Koga S, Nishikido M et al.. Donor-specific blood transfusion prolongs cardiac allograft survival in rats by low nitric oxide production and elevated serum levels of prostaglandin E₂ .  Immunology Letters. 2002;  83 119-124
• 99 Langrehr J M, Dull K E, Ochoa J B et al.. Evidence that nitric oxide production by in vivo allosensitized cells inhibits the development of allospecific CTL Transplantation.  1992;  53 632-640
• 100 Ichiguchi O, Yamaguchi Y, Goto M et al.. A significant reduction of macrophages expressing inducible nitric oxide synthase in rat hepatic allografts pretreated with donor-specific blood.  Transplantation. 1998;  65 776-785
• 101 Rodiles M, Chadee K. Novel regulation of cyclooxygenase-2 expression and prostaglandin E₂ production by IFN-gamma in human macrophages.  J Immunol. 1998;  161 2441-2448
• 102 Koga S, Luke P P, Specht S M et al.. Inhibition of the allograft response by donor specific blood transfusion: association with reduced local TH1 cytokines and nitric oxide but enhanced prostaglandin E₂ production.  Transplantation. 2000;  70 1788-1796
• 103 Plaut M, Marone G, Gillespie E. The role of cyclic AMP in modulating cytotoxic T lymphocytes. II. Sequential changes during culture in responsiveness of cytotoxic lymphocytes to cyclic AMP-active agents.  J Immunol. 1983;  131 2945-2952
• 104 Betz M, Fox B S. Prostaglandin E₂ inhibits production of Th1 lymphokines but not of Th2 lymphokines.  J Immunol. 1991;  146 108-113
• 105 Goto T, Herberman R B, Maluish A, Strong D M. Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity.  J Immunol. 1983;  130 1350-1355
• 106 Kunkel S L, Chensue S W, Phan S H. Prostaglandins as endogenous mediators of interleukin 1 production.  J Immunol. 1986;  136 186-192
• 107 Snyder D S, Beller D I, Unanue E R. Prostaglandins modulate macrophage Ia expression Nature.  1982;  299 163-165
• 108 Shelby J, Marushack M M, Nelson E W. Prostaglandin production and suppressor cell induction in transfusion-induced immune suppression Transplantation.  1987;  43 113-116
• 109 Yaron I, Jin M X, Oluwole S F, Hardy M A. Importance of the relative resistance of cord blood CD34⁺ cells to UVB in bone marrow transplantation.  Transplant Proc. 1997;  29 739
• 110 Yu S, Tu Y, Flye M W. The shift of Th1/Th2 ratios induced by portal venous administration of UVB-treated donor spleen cells prolonged mouse cardiac allografts.  Transplant Proc. 1997;  29 1162
• 111 Anderson C B, Tyler J D, Sicard G A et al.. Pretreatment of renal allograft recipients with immunosuppression and donor specific blood.  Transplantation. 1984;  38 664-668
• 112 Fehrman I, Groth C G, Lundgren G, Moller E. Improved renal graft survival in transfused uremics. A result of a number of interacting factors.  Transplantation. 1980;  30 324-327
• 113 Ettenger R B, Kerman R, Arnett L et al.. Sensitization following donor specific transfusions for living-related renal transplantation.  Transplant Proc. 1983;  15 943
• 114 Morris P J. Kidney transplantation, principles and practice. In: Fine RN, Bajaj G Renal Transplantation in Children. 5th ed. Philadelphia, PA; WB Saunders 2001 622
• 115 Miura S, Okazaki H, Sato T, Amada N, Sakurada M. Successful renal transplantation in presensitized recipients with double-filtration plasmapheresis and 15-deoxyspergualin.  Transplant Proc. 1997;  29 350-351
• 116 Sato Y, Farges O, Buffello D, Hatakeyama K, Bismuth H. Impact of 70% partial hepatectomy on administration of donor leukocytes in cardiac transplantation in rats.  Transplant Proc. 1998;  30 3873-3875
• 117 Iwaki Y, Cecka J M, Terasaki P I. The transfusion effect in cadaver kidney transplants-yes or no.  Transplantation. 1990;  49 56-59
• 118 Cicciarelli J S. UNOS Registry data: effect of transfusions. In: Terasaki PI Clinical Transplants. Los Angeles, CA; UCLA Tissue Typing Laboratory 1990 407
• 119 Ahmed Z, Terasaki P I. Effect of transfusion. In: Terasaki PI, Cecka MJ Clinical Transplants, 1991. Los Angeles, CA; UCLA Tissue Typing Laboratory 1992: 305
• 120 Chertow G M, Milford E L. Pre-transplant blood transfusion and cadaveric renal allograft outcome: data from the United Network of Organ Sharing (UNOS).  J Am Soc Nephol. 1995;  16 1077
• 121 Opelz G, Vanrenter ghem Y, Kriste G et al.. Prospective evaluaton of pretransplant blood transfusions in cadaver kidney recipients.  Transplantation. 1997;  63 964-967
• 122 Alexander J W, Light J A, Donaldson L A et al.. Evaluation of pre- and posttransplant donor specific transfusion/cyclosporine A in non-HLA identical living donor kidney transplant recipients. Cooperative clinical trials in transplantation research group.  Transplantation. 1999;  68 1117-1124